AU2001284122A1 - Vaccines against cytokines and growth factors derived from malignant tumours - Google Patents

Vaccines against cytokines and growth factors derived from malignant tumours

Info

Publication number
AU2001284122A1
AU2001284122A1 AU2001284122A AU8412201A AU2001284122A1 AU 2001284122 A1 AU2001284122 A1 AU 2001284122A1 AU 2001284122 A AU2001284122 A AU 2001284122A AU 8412201 A AU8412201 A AU 8412201A AU 2001284122 A1 AU2001284122 A1 AU 2001284122A1
Authority
AU
Australia
Prior art keywords
growth factors
vaccines against
malignant tumours
factors derived
against cytokines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284122A
Inventor
Bernard Bizzini
Helene Le Buanec
Daniel Zagury
Jean-Francois Zagury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neovacs SA
Original Assignee
Neovacs SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs SA filed Critical Neovacs SA
Publication of AU2001284122A1 publication Critical patent/AU2001284122A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2001284122A 2000-08-09 2001-08-08 Vaccines against cytokines and growth factors derived from malignant tumours Abandoned AU2001284122A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/10480 2000-08-09
FR0010480A FR2812813B1 (en) 2000-08-09 2000-08-09 USE OF IMMUNOGENS TO TREAT OR PREVENT WITHIN MALIGNANT TUMORS IMMUNE DISORDERS INDUCED BY EXTRACELLULAR FACTORS
PCT/FR2001/002575 WO2002011759A1 (en) 2000-08-09 2001-08-08 Vaccines against cytokines and growth factors derived from malignant tumours

Publications (1)

Publication Number Publication Date
AU2001284122A1 true AU2001284122A1 (en) 2002-02-18

Family

ID=8853431

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284122A Abandoned AU2001284122A1 (en) 2000-08-09 2001-08-08 Vaccines against cytokines and growth factors derived from malignant tumours

Country Status (8)

Country Link
US (2) US20040028647A1 (en)
EP (1) EP1309343B1 (en)
AU (1) AU2001284122A1 (en)
CA (1) CA2418899C (en)
DK (1) DK1309343T3 (en)
ES (1) ES2439872T3 (en)
FR (1) FR2812813B1 (en)
WO (1) WO2002011759A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828404B1 (en) * 2001-08-10 2005-07-15 Neovacs COMPOSITE SUPERIMMUNOGEN FOR BIFUNCTIONAL VACCINE USE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH STROMAL TISSUE DISORDER
FR2844514B1 (en) * 2002-09-16 2007-10-19 Neovacs STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES, COMPOSITIONS CONTAINING SAME, AND PREPARATION METHOD
FR2859725B1 (en) * 2003-09-16 2006-03-10 Neovacs HIGH EFFICIENCY PROCESS FOR OBTAINING HUMAN ANTIBODIES THAT NEUTRALIZE THE BIOLOGICAL ACTIVITY OF A HUMAN CYTOKINE
WO2005042575A2 (en) * 2003-10-30 2005-05-12 Pharmexa A/S Method for down-regulation of vegf
US20050260258A1 (en) * 2003-12-18 2005-11-24 The Texas A&M University System Use of vitelline protein B as a microencapsulating additive
DE602006020563D1 (en) * 2005-05-24 2011-04-21 Neovacs METHOD FOR PRODUCING A STABLE IMMUNOGENIC PRODUCT CONTAINING ANTIGENE HETERO COMPLEXES FROM TNF-APLHA AND A CARRIER PROTEIN
DK2419144T3 (en) 2009-04-17 2019-10-21 Univ Oxford Innovation Ltd Composition for the supply of genetic material
AU2011340477A1 (en) 2010-12-08 2013-06-20 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
BR112013025892B1 (en) * 2011-04-07 2021-01-19 Neovacs immunogenic product, unit dosage form, medical device and ifna-related kit
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677654B1 (en) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc COMPOUNDS WITH AN IMMUNOGENIC ANTI-CYTOKIN EFFECT, AN ANTIYTOSTATIC IMMUNOGENIC EFFECT OR AN ANTI-HIV INFECTION VACCINE EFFECT.
DE69333448D1 (en) * 1992-07-22 2004-04-15 Univ Princeton P53 impfstoff
US6805865B1 (en) * 1993-05-27 2004-10-19 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
AU3735095A (en) * 1994-09-30 1996-04-26 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
IT1277926B1 (en) * 1995-09-01 1997-11-12 Angeletti P Ist Richerche Bio USE OF NATURAL CYTOKINE MUTEINS AS IMMUNOGENS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO TREAT OR PREVENT
JP2001517638A (en) * 1997-09-25 2001-10-09 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Fucosil GM-1-KLH conjugate vaccine against small cell lung cancer
FR2781158B1 (en) * 1998-07-15 2002-12-13 Vacs Internat NOVEL MODIFIED NON-IMMUNOSUPPRESSIVE IMMUNOGENIC PROTEINS, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS
FR2789902A1 (en) * 1999-02-24 2000-08-25 Pf Medicament Use of enterobacterial outer membrane protein as immunogenic carrier, particularly for contraceptive and anti-cancer vaccines, provides strong humoral response

Also Published As

Publication number Publication date
US8101165B2 (en) 2012-01-24
CA2418899A1 (en) 2002-02-14
DK1309343T3 (en) 2014-01-06
US20080031849A1 (en) 2008-02-07
FR2812813A1 (en) 2002-02-15
FR2812813B1 (en) 2004-11-26
CA2418899C (en) 2014-03-11
WO2002011759A9 (en) 2003-07-17
EP1309343B1 (en) 2013-10-02
EP1309343A1 (en) 2003-05-14
US20040028647A1 (en) 2004-02-12
WO2002011759A1 (en) 2002-02-14
ES2439872T3 (en) 2014-01-27

Similar Documents

Publication Publication Date Title
AU2002336760A1 (en) Mutable vaccines
SI1326638T1 (en) Vaccines against cancers
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
AU4943200A (en) Modified cytokine
AU2002311869A1 (en) Breast cancer-associated genes and uses thereof
AU2001231204A1 (en) Genetically engineered tumor cell vaccines
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
AU2002319338A1 (en) Cancer specific oligosaccharide sequences and use thereof
AU2001284122A1 (en) Vaccines against cytokines and growth factors derived from malignant tumours
AU2001278338A1 (en) Methods and compositions for modulating tumor growth
AU2002349543A1 (en) Tumor antigens
AU2457701A (en) Methods and products for tumor immunotherapy using cytokines
AU2002356898A1 (en) Gene amplification and overexpression in cancer
AU2003289603A1 (en) Tumor vaccine
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
HUP0300772A3 (en) Medicament for the immunotherapy of malignant tumours
AU2002312373A1 (en) Structural and cytoskeleton-associated proteins
AU2002320079A1 (en) Vaccines, immunotherapeutics and methods of using the same
AU2001296258A1 (en) Phototherapeutic and chemotherapeutic immunotherapy against tumors
AU2002236065A1 (en) Papillomavirus vaccines
AU2001288940A1 (en) Gene and sequence variation associated with cancer
AU5632500A (en) Cancer associated antigens and uses therefor
AU2001281048A1 (en) Floral induction gene
AU5811600A (en) Vaccine
AU2001253852A1 (en) Preprocalcitonin as tumor rejection antigen precursor and uses thereof